News Search Results
Aug 28, 2026, 07:00 ET CREATE Medicines Expands Clinical In Vivo CAR Pipeline and LNP Technology Suite by Forming Strategic Collaboration With WestGene
populations, delivery systems, CAR architectures, expression profiles, dosing strategies, and disease settings.About CREATE MedicinesCREATE Medicines is a clinical-stage biotech pioneering in vivo CAR therapy. Its proprietary mRNA-LNP platform directly programs immune cells
More news about: CREATE Medicines, Inc.
Jul 31, 2026, 07:00 ET CREATE Medicines Expands Targeted In Vivo CAR Platform Through Strategic Research Collaboration and Exclusive License Agreement with Monash University
vivo cell therapies and pairing our LNP technology with CREATE's platform is a powerful step toward solving it."About CREATE MedicinesCREATE Medicines is a clinical-stage biotech pioneering in vivo CAR therapy. Its proprietary mRNA-LNP platform directly programs immune cells inside
More news about: CREATE Medicines, Inc.
Jul 30, 2026, 07:00 ET CREATE Medicines Receives Approval to Initiate First-in-Human Phase 1/2 Clinical Trial of In Vivo CAR-T Candidate CRT-402 for Autoimmune Diseases
administration paradigm. In preclinical studies, CRT-402 demonstrated deep and durable B cell depletion in nonhuman primates.About CREATE MedicinesCREATE Medicines is a clinical-stage biotech pioneering in vivo CAR therapy. Its proprietary mRNA-LNP platform directly programs immune cells inside
More news about: CREATE Medicines, Inc.
Jul 27, 2026, 06:00 ET Bambusa Therapeutics Reports Potentially Transformative Preliminary Proof-of-Concept Results for BBT001 in Atopic Dermatitis, Reinforcing Its Best-in-Disease Potential
advancement of a potential novel therapy that, if approved, could reshape the treatment landscape for atopic dermatitis.""We founded Bambusa to create medicines that could redefine the standard of care, rather than deliver incremental improvement," said Shanshan Xu, M.D., Ph.D., Co-Founder and Chief Executive
More news about: Bambusa Therapeutics
May 14, 2026, 08:10 ET CREATE Medicines Strengthens Clinical and Scientific Advisory Board with Appointment of Georg Schett, MD, Margrit Wiesendanger, MD, PhD, and Christopher Jewell, PhD
University of Wisconsin. He is a member of the PhRMA Advisory Committee and has served on White House OSTP committees.About CREATE MedicinesCREATE Medicines is a clinical-stage biotechnology company pioneering in vivo immune programming. The company's proprietary mRNA-LNP platform directly
More news about: CREATE Medicines, Inc.
May 14, 2026, 08:00 ET CREATE Medicines Announces $122 Million Series B Financing to Advance In Vivo CAR Pipeline in Autoimmune Disease and Oncology
programming capabilities position it to play an important role in the future of autoimmune disease and oncology."About CREATE MedicinesCREATE Medicines is a clinical-stage biotechnology company pioneering in vivo immune programming. The company's proprietary mRNA-LNP platform directly
More news about: CREATE Medicines, Inc.
Apr 23, 2026, 08:02 ET CREATE Medicines Doses First Patient in Phase 1/2 Study of MT-304, a First-in-Class Multi-immune In Vivo CAR Therapy Targeting HER2-Positive Solid Tumors
offer a new therapeutic paradigm that may overcome resistance patterns and deliver more sustained disease control.About CREATE MedicinesCREATE Medicines is a clinical-stage biotech pioneering in vivo CAR therapy. Its proprietary mRNA-LNP platform directly programs immune cells inside
More news about: CREATE Medicines, Inc.
Apr 17, 2026, 11:00 ET CREATE Medicines to Showcase Multi-immune In Vivo CAR T, CAR NK, and All-RNA RetroT Platform at AACR 2026
#: 20Abstract #: LB155More information is available on the AACR Annual Meeting website.About CREATE MedicinesCREATE Medicines is a clinical-stage biotech pioneering in vivo CAR therapy. Its proprietary mRNA-LNP platform directly programs immune cells inside
More news about: CREATE Medicines, Inc.
Feb 02, 2026, 16:00 ET CREATE Medicines Demonstrates Complete B Cell Depletion and Repeatable Dosing in Non-human Primates with In Vivo CAR-T Platform
https://www.keystonesymposia.org/conferences/conference-listing/meeting/onpage-program/K22026About CREATE MedicinesCREATE Medicines is a clinical-stage biotech pioneering in vivo CAR therapy. Its proprietary mRNA-LNP platform directly programs immune cells inside
More news about: CREATE Medicines, Inc.
Jan 08, 2026, 16:00 ET CREATE Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
Time: Thursday, January 15th: 9:30 a.m. PTLocation: The Westin St. Francis, San Francisco, CAAbout CREATE MedicinesCREATE Medicines is a clinical-stage biotech pioneering in vivo CAR therapy. Its proprietary mRNA-LNP platform directly programs immune cells inside
More news about: CREATE Medicines, Inc.
Dec 27, 2025, 06:00 ET Weathering the Storm
with students who dream of making a meaningful impact in their community."When I grow up, I want to be a scientist and work in medicine to create medicines for the people," says 12-year-old Gabriel.Margaret has also benefited from the programme's holistic support. Like many girls her age, she
More news about: Education Cannot Wait
Dec 09, 2025, 08:00 ET CREATE Medicines Doses First Patient in Frontline HCC Trial Evaluating MT-303, an In Vivo CAR Therapy, in Combination with Standard-of-Care Immunotherapy
coordinated and sustained immune responses represent an urgent and unmet need for the global HCC patient community.About CREATE MedicinesCREATE Medicines (formerly Myeloid Therapeutics) is a clinical-stage biotech pioneering in vivo multi-immune programming. Its proprietary mRNA-LNP
More news about: CREATE Medicines, Inc.
Nov 07, 2025, 09:00 ET CREATE Medicines Announces Positive First-in-Human Results for MT-302
while achieving repeatable dosing and controllable anti-tumor activity. About CREATE MedicinesCREATE Medicines (formerly Myeloid Therapeutics) is a clinical-stage biotech pioneering in vivo multi-immune programming. Its proprietary mRNA-LNP
More news about: CREATE Medicines, Inc.
Nov 03, 2025, 08:00 ET CREATE Medicines to Present Late-Breaking Clinical Data on MT-302 at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
Convention Center, Potomac Ballroom, National Harbor, MD About CREATE MedicinesCREATE Medicines (formerly Myeloid Therapeutics) is a clinical-stage biotech pioneering in vivo multi-immune programming. Its proprietary mRNA-LNP
More news about: CREATE Medicines, Inc.
Oct 29, 2025, 18:34 ET CREATE Medicines Unveils All-RNA T-Cell Engineering Platform: RetroT Enables Site-Specific, Durable CAR integration In Vivo
https://meetings.cshl.edu/meetings.aspx?meet=IMMENG About CREATE Medicines CREATE Medicines (formerly Myeloid Therapeutics) is a clinical-stage biotech pioneering in vivo multi-immune programming. Its proprietary
More news about: CREATE Medicines, Inc.
Oct 28, 2025, 08:00 ET CREATE Medicines and Amsterdam University Medical Center Initiate First In Vivo CAR Therapy Trial in Frontline Setting for Solid Tumors
treatments, personalization of treatment and supportive care. About CREATE Medicines CREATE Medicines (formerly Myeloid Therapeutics) is a clinical-stage biotech pioneering in vivo multi-immune programming. Its proprietary
More news about: CREATE Medicines, Inc.
Oct 08, 2025, 09:00 ET Alpha Fusion and Kobe City Medical Center General Hospital Establish At-211 Investigational Drug Supply System
the domestic investigational drug supply system now in place, we will accelerate the international rollout of At-211 drug discovery, aiming to create medicines for patients currently without treatment options.
More news about: Alpha Fusion Inc
Oct 08, 2025, 08:00 ET CREATE Medicines Strengthens Executive Team with Appointment of Veteran Biopharma Leader Allan L. Shaw as CFO and CBO
appointment marks an important inflection point for CREATE Medicines as we build on our scientific leadership and prepare for the next phase of our journey," said Daniel Getts, Ph.D., Co-Founder and Chief Executive Officer of CREATE Medicines. "His unique combination of strategic insight, transactional
More news about: CREATE Medicines, Inc.
Oct 06, 2025, 12:14 ET New Survey: Most Americans Believe Plasma Donation Saves Lives, Yet Few Have Donated
@chronically.lils. "Donating plasma helps create medicines that help me and many others thrive! Thanks to my plasma-derived therapy, I can now run, hike, climb, and be active and present in my daily life
More news about: The Plasma Protein Therapeutics Association
Oct 06, 2025, 08:00 ET Myeloid Therapeutics Rebrands as CREATE Medicines, Focused on Transforming Immunotherapy Through RNA-Based In Vivo Multi-Immune Programming
<12 months with low-cost manufacturing. About CREATE Medicines CREATE Medicines (formerly Myeloid Therapeutics) is a clinical-stage biotech pioneering in vivo multi-immune programming. Its proprietary
More news about: CREATE Medicines, Inc.
Oct 02, 2025, 15:40 ET Psilera Inc. Secures National Institutes of Health Grant for AUD Research
treatment. About Psilera:Psilera is a biotechnology research and development company founded to create medicines that change the way the world thinks. By harnessing the potential of natural products, the company advances neuroplastic therapies to help patients
More news about: Psilera Inc.